Andreas Engert

6.0k citations
179 papers · 3.9k indexed · 1 hit paper · h-index 30

Impact in

Papers in

Andreas Engert

168 papers receiving 3.8k citations

Hit Papers

Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. 1998 · 724 citations
7241998202620072016200400600

Peers

Andreas Engert
Comparison fields: 5 of 124
  • Pathology and Forensic Medicine 2.3k
  • Genetics 901
  • Oncology 1.8k
  • Immunology 997
  • Neurology 657
Replace Kaarle Franssila with:
Kaarle Franssila Finland
B.K. Dallaire United States
Dana A. Kennedy United States
Radhakrishnan Ramchandren United States
M. S. Czuczman United States
Andreas Viardot Germany
Isabelle Bence‐Bruckler Canada
Gunilla Enblad Sweden
Michelle A. Fanale United States
Andres Forero‐Torres United States
Andreas Engert relative to Kaarle Franssila Finland Kaarle Franssila's profile →
Citations per field
00.5×1.7×
Kaarle Franssila · 1×
Citations per year

Countries citing papers authored by Andreas Engert

Since Specialization
Citations

This map shows the geographic impact of Andreas Engert's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andreas Engert with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andreas Engert more than expected).

Fields of papers citing papers by Andreas Engert

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andreas Engert. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andreas Engert. The network helps show where Andreas Engert may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Andreas Engert, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Andreas Engert Line = papers co-authored together Andreas Engert links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown
#Work
1 20230
2 20208
3 20192
4
B-CAP (brentuximab vedotin, cyclophosphamide, doxorubicin and predniso(lo)Ne) in Older Patients with Advanced-Stage Hodgkin Lymphoma: Results of a Phase II Intergroup Trial By the German Hodgkin Study Group (GHSG) and the Nordic Lymphoma Group (NLG)
20180
5 20141
6 20123
7
Entwicklung von Anti-CD30-Radioimmunkonstrukten zur Behandlung des Hodgkin-Lymphoms – Studien an Zellkulturen und Tieren
20106
8
Reformperspektiven einer Umwandlung von Fremd- in Eigenkapital (Debt-Equity Swap) im Insolvenzplanverfahren
20091
9
Vom Wert der Wahlfreiheit: Eine empirische Analyse der Societas Europaea als Rechtsformalternative
20093
10 200921
11 20091
12
Increased doses of an anti-CD30 antibody, MDX-060, results in prolonged progression free survival in subjects with CD30 positive lymphoma.
20082
13 200616
14 2004112
15
2-weekly vs 3-weekly CHOP with and without Etoposide in Young Patients with Low-Risk Aggressive Non-Hodgkins Lymphoma Results of the Completed NHL-B-1 Trial of the DSHNHL
20021
16 200230
17
Combined systemic and intraventricular chemotherapy in primary CNS lymphoma: Superior results in patients younger than 60 years
20011
18 20012
19 19941
20 199410

About Andreas Engert

Andreas Engert is a scholar working on Pathology and Forensic Medicine, Genetics, Oncology, Radiology, Nuclear Medicine and Imaging and Hematology, having authored 179 papers that have together received 3.9k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (94 papers), Lung Cancer Treatments and Mutations (37 papers), Monoclonal and Polyclonal Antibodies Research (35 papers), Chronic Lymphocytic Leukemia Research (29 papers), CAR-T cell therapy research (15 papers), Toxin Mechanisms and Immunotoxins (14 papers), CNS Lymphoma Diagnosis and Treatment (13 papers) and Corporate Governance and Law (10 papers). The work is most often cited by research in Pathology and Forensic Medicine (2.3k citations), Genetics (901 citations), Oncology (1.8k citations), Immunology (997 citations) and Neurology (657 citations). Andreas Engert has collaborated with scholars based in Germany, United States and United Kingdom. Frequent co-authors include Volker Diehl, Corinne Brillant, Renaud Capdeville, Corinne Haïoun, Dengyan Ma, Peter Johnson, F Reyes, Nicolas Ketterer, Michaela Feuring Buske and H Tilly. Their work appears in journals such as Blood, Journal of Clinical Oncology, Annals of Oncology, JNCI Journal of the National Cancer Institute and HemaSphere.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026